Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
06:30am, Monday, 22'nd Jul 2024
CAMBRIDGE, Mass., July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
CAMBRIDGE, Mass. , July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
06:30am, Thursday, 11'th Jul 2024
CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina
Nuvalent: Making Precise Progress In Its Oncology Pipeline
07:00am, Monday, 24'th Jun 2024
Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment resist
3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally
06:00am, Monday, 24'th Jun 2024
Generally, when the masses – including the market's heavy hitters – decide to bet against a security, it's best to avoid it. However, the unique nuances involved with shorting a company opens the
Nuvalent (NUVL) CEO On The Future Of Cancer Treatments
12:19pm, Monday, 17'th Jun 2024
Nuvalent is a clinical stage biopharma company that develops treatments for cancer patients. CEO James Porter weighs in on the FDA breakthrough therapy designation for NVL-655.
Nuvalent: NVL-655 Could Bring Blockbuster Potential
07:15am, Friday, 14'th Jun 2024
Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
06:30am, Wednesday, 29'th May 2024
CAMBRIDGE, Mass. , May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
04:01pm, Thursday, 16'th May 2024
CAMBRIDGE, Mass. , May 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
06:30am, Thursday, 09'th May 2024
Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 Strong financial position with operating runway anticipated into 2027 C
Why Earnings Season Could Be Great for Nuvalent (NUVL)
11:26am, Wednesday, 08'th May 2024
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile Zidesamtinib shown to be
CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
Well-capitalized with operating runway anticipated into 2027 CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on cre
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
06:15am, Tuesday, 27'th Feb 2024
CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
